Ajanta Pharma Limited (NSE:AJANTPHARM)

Ajanta Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	1,751	1,295	3,298	2,064	1,775
Short-Term Investments	-	-	-	-	-	250
Trading Asset Securities	-	4,387	3,301	5,103	1,219	1,757
Cash & Short-Term Investments	6,139	6,139	4,595	8,401	3,282	3,782
Cash Growth	33.58%	33.58%	-45.30%	155.96%	-13.21%	40.33%
Accounts Receivable	-	11,827	12,468	10,569	10,198	7,384
Other Receivables	-	412	696.6	459.2	460.5	862.2
Receivables	-	12,265	13,505	11,202	10,722	8,327
Inventory	-	9,039	8,284	8,156	7,911	7,665
Prepaid Expenses	-	245.8	259.2	164.4	155.8	138.4
Other Current Assets	-	742.7	666.4	416.2	573.6	364.2
Total Current Assets	-	28,430	27,309	28,340	22,645	20,276
Property, Plant & Equipment	-	18,918	17,210	16,982	16,474	16,296
Long-Term Investments	-	284.4	227.4	290	294.2	39.5
Other Intangible Assets	-	465.2	146.6	77.5	90.2	107.9
Long-Term Deferred Tax Assets	-	1,864	1,345	967.7	555.5	501
Other Long-Term Assets	-	187.6	146.4	133.4	497.1	566.8
Total Assets	-	50,150	46,384	46,790	40,556	37,787
Accounts Payable	-	4,542	4,632	4,228	3,272	3,739
Accrued Expenses	-	892.1	671.3	356.8	375.9	352.1
Short-Term Debt	-	60.9	30.5	38.4	94.9	63.9
Current Portion of Leases	-	101.1	102.7	94.3	64.6	115.9
Current Income Taxes Payable	-	405.3	447.7	330.7	79.4	489.2
Current Unearned Revenue	-	3.3	3.3	3.3	3.3	3.3
Other Current Liabilities	-	3,956	3,070	6,342	2,584	1,723
Total Current Liabilities	-	9,961	8,958	11,393	6,474	6,486
Long-Term Leases	-	347.2	235.2	262	185.7	197.7
Long-Term Unearned Revenue	-	20	23.4	26.7	30	33.4
Long-Term Deferred Tax Liabilities	-	1,105	1,085	977.2	1,019	921.7
Other Long-Term Liabilities	-	344.6	274.1	228.4	204.1	180.9
Total Liabilities	-	12,247	10,710	12,910	7,912	7,831
Common Stock	-	249.8	251.8	251.8	170.8	173
Additional Paid-In Capital	-	36.6	1.8	-	-	-
Retained Earnings	-	37,434	35,254	33,523	32,495	29,726
Comprehensive Income & Other	-	182.1	166.2	105	-22.1	57.7
Shareholders' Equity	37,903	37,903	35,674	33,880	32,643	29,956
Total Liabilities & Equity	-	50,150	46,384	46,790	40,556	37,787
Total Debt	509.2	509.2	368.4	394.7	345.2	377.5
Net Cash (Debt)	5,629	5,629	4,227	8,006	2,937	3,404
Net Cash Growth	33.17%	33.17%	-47.20%	172.60%	-13.73%	78.36%
Net Cash Per Share	45.05	44.97	33.55	62.49	22.65	26.06
Filing Date Shares Outstanding	124.92	125.68	126.68	125.91	128.12	129.8
Total Common Shares Outstanding	124.92	125.68	126.68	125.91	128.12	129.8
Working Capital	-	18,469	18,352	16,947	16,171	13,790
Book Value Per Share	301.59	301.59	281.60	269.07	254.78	230.79
Tangible Book Value	37,438	37,438	35,527	33,802	32,553	29,848
Tangible Book Value Per Share	297.88	297.88	280.44	268.45	254.08	229.96
Land	-	1,467	1,488	1,577	1,575	1,556
Buildings	-	8,113	6,174	6,057	5,870	5,677
Machinery	-	16,364	14,692	13,879	13,276	12,614
Construction In Progress	-	1,763	2,565	2,095	1,529	1,082
Leasehold Improvements	-	-	-	-	10.9	11.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.